RxDoctor Payments Data

Abdulgadir Adam, MD

Pulmonary Disease · Royal Oak, MINPI 1942493838

Payments from drug & device makers

$6,836in general payments, 2019–2025

Across 70 payments — averaging $97.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$2K
  • Steris Corporation$2K
  • Intuitive Surgical$826
  • Merit Medical Systems Inc$744
  • GSK$345
  • Johnson & Johnson$332
  • plus $679 from 10 others

What the payments were for

  • Travel & lodging$4,84371%
  • Food & beverage$1,99329%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,836 in reported general payments places this provider in the 70th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$112,525
Medicare patients
319
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$44,945
Breo ElliptaFluticasone/Vilanterol42$19,473
Spiriva RespimatTiotropium Bromide23$18,244
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$15,259
Incruse ElliptaUmeclidinium Bromide14$6,220
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,259
Albuterol Sulfate HfaAlbuterol Sulfate68$3,112
SymbicortBudesonide/Formoterol Fumarate11$2,581
Roflumilast14$1,107
Ventolin HfaAlbuterol Sulfate12$991
Montelukast Sodium42$500
Fluticasone Propionate15$186
Omeprazole12$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$345$85,898148 claims
Boehringer IngelheimSpiriva Respimat$13$18,24423 claims
AstraZenecaSymbicort$27$2,58111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →